Hidonac

Hidonac is a prescription solution for injection containing the mucolytic agent acetylcysteine. Marketed in the European Union, the product is supplied as an intravenous solution (strength not specified) and is used under medical supervision for respiratory and toxicology indications. It belongs to the mucolytic drug class and is also classified as an antidote for acetaminophen overdose. The formulation is intended for administration by healthcare professionals in hospital or emergency settings.

Hidonac is employed in clinical practice for several acute and supportive indications related to the respiratory system and acetaminophen toxicity.

- Treatment of acute acetaminophen (paracetamol) poisoning to replenish glutathione and reduce hepatic injury. - Mucolytic therapy in patients with thick, tenacious sputum associated with chronic bronchitis, COPD, or cystic fibrosis. - Adjunctive management of asthma or bronchiolitis exacerbations where mucus clearance is impaired. - Supportive care in severe respiratory infections, such as pneumonia, to facilitate airway clearance. - Use in peri‑operative settings to reduce mucus viscosity during anesthesia or mechanical ventilation.

Adverse reactions to Hidonac may vary in frequency and severity; they are typically reported after intravenous administration.

Common: - Transient nausea or vomiting. - Mild headache. - Flushing or warmth at the infusion site. - Low‑grade fever or chills. - Diarrhea or loose stools. - Metallic taste in the mouth. - Dizziness or light‑headedness. - Injection site pain or irritation. - Transient increase in heart rate (tachycardia).

Serious: - Anaphylactoid or severe allergic reactions, including rash, bronchospasm, or hypotension. - Acute bronchospasm or respiratory distress. - Hepatic enzyme elevation in patients with pre‑existing liver disease. - Severe hypotension requiring vasopressor support. - Pulmonary edema in susceptible individuals. - Cardiac arrhythmias in patients with underlying heart disease.

Before prescribing Hidonac, clinicians should evaluate patient history and clinical status to minimize risk of adverse events.

- Assess for known hypersensitivity to acetylcysteine or any component of the formulation. - Use caution in patients with asthma or reactive airway disease, as bronchospasm may be precipitated. - Monitor liver function tests in individuals with existing hepatic impairment or chronic alcohol use. - Adjust infusion rate in patients with cardiovascular instability to avoid sudden hypotension. - Avoid use in patients with severe renal failure without specialist guidance. - Consider baseline coagulation status, as high‑dose therapy may affect platelet function. - Ensure appropriate resuscitation equipment is available during administration.

Intravenous acetylcysteine can interact with other medications; awareness of these interactions helps optimize safety.

Avoid: - Concomitant use of nitroglycerin or other vasodilators may exacerbate hypotension. - Simultaneous administration with activated charcoal can reduce acetylcysteine absorption if given orally (not relevant for IV) but avoid mixing in same line.

Use with caution: - Anticoagulants (e.g., warfarin, heparin) may have enhanced anticoagulant effect; monitor coagulation parameters. - Loop diuretics may increase risk of electrolyte disturbances when combined with high‑dose acetylcysteine. - Beta‑adrenergic agonists (e.g., albuterol) may increase bronchial secretions; monitor respiratory status. - Drugs metabolized by hepatic glutathione pathways (e.g., acetaminophen) require dose adjustments.